睿知中国医院研究地图
候选清单

正在招募视神经脊髓炎谱系疾病重症肌无力I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

ClinicalTrials.gov 上登记的一项视神经脊髓炎谱系疾病和重症肌无力开放试验,由华中科技大学同济医学院附属同济医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07526493,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Male or female participants unwilling to practice contraception from the time of informed consent until 6 months after treatment completion.

    排除标准第 19 条

    History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulation therapy.

    排除标准第 21 条

  3. Bone Marrow Function: White blood cell count ≥1×10⁹/L; absolute neutrophil count ≥1×10⁹/L (no treatment with colony-stimulating factors within 2 weeks prior to the test); hemoglobin ≥60 g/L.

    排除标准第 4 条

    Liver Function: ALT ≤3×ULN (except if elevated due to inflammatory myopathy); AST ≤3×ULN (except if elevated due to inflammatory myopathy); Indirect bilirubin (IBIL) ≤1.5×ULN (except for Gilbert's syndrome); Total bilirubin ≤3.0×ULN.

    排除标准第 5 条

    Renal Function: Creatinine clearance (CrCl) ≥30 mL/min (eGFR ≥30 mL/min/1.73m²) (calculated by Cockcroft-Gault formula, except for acute decreases in CrCl due to the disease itself).

    排除标准第 6 条

    Coagulation Function: International normalized ratio (INR) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN.

    排除标准第 7 条

  4. History of active/unresolved malignant tumors within the past 5 years.

    排除标准第 10 条

    Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer above the detection limit; positive for hepatitis C virus (HCV) antibody with detectable peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody; or positive for Treponema pallidumserology.

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07526493,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

    排除标准:Exclusion Criteria:

    1. History of severe drug allergy or allergic diathesis.
    2. Presence of or suspected uncontrolled or treatment-requiring fungal, bacterial, viral, or other infections.
    3. Organ function that does not meet the following requirements (except for abnormalities caused by the autoimmune disease itself):
    4. Bone Marrow Function: White blood cell count ≥1×10⁹/L; absolute neutrophil count ≥1×10⁹/L (no treatment with colony-stimulating factors within 2 weeks prior to the test); hemoglobin ≥60 g/L.
    5. Liver Function: ALT ≤3×ULN (except if elevated due to inflammatory myopathy); AST ≤3×ULN (except if elevated due to inflammatory myopathy); Indirect bilirubin (IBIL) ≤1.5×ULN (except for Gilbert's syndrome); Total bilirubin ≤3.0×ULN.
    6. Renal Function: Creatinine clearance (CrCl) ≥30 mL/min (eGFR ≥30 mL/min/1.73m²) (calculated by Cockcroft-Gault formula, except for acute decreases in CrCl due to the disease itself).
    7. Coagulation Function: International normalized ratio (INR) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN.
    8. Cardiac Function: Left ventricular ejection fraction (LVEF) ≥55% and no clinically significant cardiac disease.
    9. Subjects with a history indicative of congenital immunoglobulin deficiency.
    10. History of active/unresolved malignant tumors within the past 5 years.
    11. Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer above the detection limit; positive for hepatitis C virus (HCV) antibody with detectable peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody; or positive for Treponema pallidumserology.
    12. History of definite psychiatric disorders or history of substance abuse involving psychotropic drugs that cannot be discontinued.
    13. Participation in any other clinical trial within 3 months prior to enrollment.
    14. Prior treatment with CAR-T cell therapy.
    15. History of severe adverse reactions to cyclophosphamide or fludarabine.
    16. History of other autoimmune diseases (e.g.,Crohn's disease, systemic lupus erythematosus) that, within the past 2 years, have resulted in end-organ damage or required systemic immunosuppressive therapy (excluding the disease populations specified for enrollment in the study protocol).
    17. Myasthenia gravis crisis not effectively controlled within 2 weeks prior to enrollment.
    18. History of cerebrovascular accident, including transient ischemic attack or stroke, within 6 months prior to enrollment.
    19. Male or female participants unwilling to practice contraception from the time of informed consent until 6 months after treatment completion.
    20. Any medical condition that may interfere with the assessment of the safety or efficacy of the study treatment.
    21. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulation therapy.
    22. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.

    引自 ClinicalTrials.gov, NCT07526493, 参与标准,读取于 2026年11月10日。

    这些信息从哪里来

    登记记录

    ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07526493,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

    疾病与医院

    本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

    没有收录的内容

    登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

    提出更正ClinicalTrials.gov NCT07526493